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Background: We examined the effect of exogenous factor XIII (FXIII) concentrate in patients with prolonged air
leak (PAL) after pulmonary lobectomy for non-small cell lung cancer.
Methods: We performed a retrospective analysis of 297 patients who underwent pulmonary lobectomy between
July 2007 and March 2014: 90 had an air leak on the first postoperative day, which resolved spontaneously within 5
days in 53 cases (SR group). FXIII concentrate was administered to the remaining 37 patients (PAL group) for 5 days.
This group was subdivided into those in whom the air leak resolved during FXIII treatment (EF group) and those
who needed additional intervention (inEF group). The clinical and perioperative characteristics of the groups were
compared.
Results: Although plasma FXIII activity did not differ significantly between the SR and PAL groups before surgery or
on the fifth postoperative day, the proportional perioperative fall in FXIII activity was significantly greater in the SR
group (33%) than the PAL group (22%, p = 0.044) and inEF group (14%, p = 0.048). On the fifth postoperative day,
FXIII activity was significantly lower in the EF group than in the inEF group (74% versus 91%, p = 0.030). The optimal
cut-off point for postoperative plasma FXIII activity to distinguish between the EF and inEF groups was 86%.
Conclusions: Insufficient plasma FXIII consumption and lower postoperative FXIII activity may play a role in the
resolution of PAL, and exogenous FXIII concentrate may be an effective, safe and non-invasive treatment.
Keywords: Pleural air leak, Postoperative care, Lung cancer surgeryBackground
Prolonged air leak (PAL) is a common complication of
pulmonary resection, occurring in 8–26% of patients
undergoing pulmonary lobectomy [1]. It is associated
with prolonged hospital stay [2,3] and other complica-
tions such as empyema [4]. Moreover, PAL occasionally
requires further surgery, despite recent progress in the
development of conservative treatments [1]. Older age,
low body mass index (BMI) [5], poor wound-healing char-
acteristics, low forced-expiratory volume (FEV) [6,7], ex-
tensive pleural adhesions [6], and upper or bilobectomy
[6,8-10] reportedly increase the risk of PAL after lung re-
section. Diabetes mellitus, and low serum albumin and* Correspondence: m1364552@msic.med.osaka-cu.ac.jp
Department of Cardiovascular Surgery, Osaka City University Graduate School
of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
© 2014 Inoue et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.cholinesterase concentrations, all of which reflect im-
paired wound healing, might also be risk factors [11].
Pulmonary air leak normally resolves spontaneously if
there is adequate chest drainage. If the pulmonary fistula
persists, chemical pleurodesis may be undertaken with
OK-432 (Picibanil®), tetracycline antibiotics, talc slurry,
autologous blood or 50% glucose solution [12,13]. The
intrathoracic administration of diluted fibrin glue, a fi-
brinogen solution containing blood coagulation factor
XIII (FXIII) and thrombin, has also been reported to be
effective [14].
Blood coagulation factor XIII stabilizes fibrin clot and
also plays a role in wound healing. In gastrointestinal
surgery, administration of exogenous FXIII concentrate
is reportedly effective for healing wounds and closing fis-
tulae in patients with low perioperative plasma FXIIItd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Flow chart of patient enrollment and classification.
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http://www.biomedcentral.com/1471-2482/14/109activity [15-17]. In thoracic surgery, exogenous FXIII
concentrate has been used to treat persistent chy-
lothorax [18]; however, little is known about the effect of
FXIII when seeking to close a PAL.
The aim of this study was to examine the therapeutic
effect of the systemic administration of exogenous FXIII
concentrate for patients with PAL after pulmonary lob-
ectomy for non-small-cell lung cancer, and to identify
differences between patients who responded and who
did not respond to treatment.
Patients and methods
The medical records of 297 patients who underwent
elective pulmonary lobectomy with mediastinal lymph
node dissection for non-small-cell lung cancer at Osaka
City University Hospital, Japan, between July 2009 and
March 2014 were analyzed. Of these, 14 were excluded
from the analysis because of incomplete data (five pa-
tients), the perioperative transfusion of blood or blood
products (eight patients) and additional treatment for
massive air leak within the first five perioperative days
(one patient). Ultimately, the records of 283 patients
were examined. No patients required postoperative
mechanical ventilation or developed a bronchopleural
fistula.
Surgery was performed through an axillary mini-
thoracotomy (assisted by video) or posterolateral thora-
cotomy (when extended lobectomy, for example, chest
wall resection, pulmonary arterioplasty or bronchoplasty,
was necessary). During surgery, the presence of pulmon-
ary air leak was tested by submerging the residual lung
parenchyma in sterile saline solution and inflating it to a
pressure of 15 cmH2O. Significant air leaks were ad-
dressed by additional suturing, applying polyglycolic acid
sheets, or both. When considered necessary, fibrin glue
was also sprayed on the lung surface to treat small al-
veolar air leaks. In all cases, a four lumen 24 French sili-
con chest tube was inserted once surgery was complete,
and suction applied at −10 to −15 cmH2O until the next
morning. On the first postoperative day, air leak and in-
trathoracic pressure were assessed by the surgeons, and
suction was replaced by a water seal unless there was a
massive air leak. Chest tubes were removed if there was
no detectable air leak and less than 300 mL had been
drained in the previous 24 h. When air leak persisted
until the fifth postoperative day, 24 mL FXIII concen-
trate (Fibrogammin P®; CSL Behring, Tokyo, Japan) was
administered intravenously once daily for 5 days. When
an air leak still persisted after the 5-day course of FXIII
concentrate had been completed, other methods of
treatment such as pleurodesis, bronchial embolization or
secondary operation were undertaken. Routine blood
tests including plasma FXIII activity were measured be-
fore operation and on the fifth postoperative day. Plasmafactor XIII activity was measured by means of a synthe-
sized substrate assay, for which the normal range is con-
sidered to be 70–140% [19]. Change ratio in postoperative
plasma Factor XIII activity were calculated by subtracting
plasma FXIII activity on the fifth postoperative day from
that measured before surgery, divided by the preoperative
FXIII activity for each patient.
Of the cohort of 283 patients, 90 (31.8%) had an air
leak on the first postoperative day. These patients were
divided into three groups: patients were allocated to
group SR (Spontaneous Resolution) if the air leak re-
solved spontaneously within 5 days (n = 53), to group EF
(EFfective) if the air leak resolved during the 5-day
course of FXIII concentrate (n = 26) or to group inEF
(inEFfective) if additional treatment was required to stop
the air leak despite administration of FXIII concentrate
(n = 11). The PAL group comprised patients in both the
EF and inEF groups (n = 37). The allocation of patients
to each group is summarized in the schematic shown in
Figure 1.
First, the SR and PAL groups were compared to estab-
lish the perioperative risk factors for PAL. Thereafter,
the EF and inEF groups were compared to find predic-
tors that exogenous FXIII concentrate administration
would be beneficial. The independent variables collected
were age, sex, BMI, smoking status, presence of comorbid
chronic obstructive lung disease (COPD) and interstitial
Table 1 Characteristics of the 90 patients with air leak on
the first postoperative day after pulmonary lobectomy
Factor n = 90
Male sex 72 (80%)
Age (years) 67 (44–80)
BMI kg/m2 21.2 (14.3–30.6)
Smoking Index 900 (0–3000)
Never-smoker 14 (16%)
Asbestos exposure 18 (20%)
FEV1.0% 71.4 (33.9–89.6)
DLCO% 88.1 (55.1–186.6)
COPD/IP (%) 53 (59%)




Duration of air leak (days) 4 (2–21)
Repair air leak during operation
No 3 (3%)
Fibrin glue only 9 (10%)
Suture only 4 (5%)
PGA sheet and fibrin glue 2 (2%)
Suture and fibrin glue 24 (27%)
Suture, PGA and fibrin glue 48 (53%)
Air leak at first postoperative day
Forced expiratory only 36 (40%)
Expiratory only 42 (47%)
Continuous 12 (13%)
Duration of air leakage (days) 4 (2–21)
Duration of drainage (days) 6 (2–29)
Drainage amount in first 5 days (ml) 1135 (365–2775)
Results are expressed as median and range.
Abbreviations: BMI body mass index, COPD chronic obstructive pulmonary
disease, DLCO carbon monoxide diffusing capacity, FEV1.0% forced expiratory
volume in 1 s (predicted), IP interstitial pneumonia, Pleural adhesion pleural
adhesion covering more than the surface of one lobe was classified as major,
and less than the surface of one lobe as minor.
Inoue et al. BMC Surgery 2014, 14:109 Page 3 of 8
http://www.biomedcentral.com/1471-2482/14/109pneumonia (IP) based on the radiological findings of em-
physematous or honeycomb changes, details of surgery
and the findings of perioperative laboratory investigations.
The extent of air leakage during the drainage period was
categorized and recorded according to the four qualitative
categories developed by Cerfolio and colleagues [20]. We
also recorded information about other potential influences
such as the history of lung disease and treatments, the
presence of vascular disease, hematologic disease or
autoimmune disorders, and the use of antiplatelet drugs,
anticoagulant drugs or systemic corticosteroids. As these
factors were only found to be present in a few patients,
these were excluded from the final analysis.
The study was performed in accordance with the
Declaration of Helsinki and received approval from the
institutional review board of the Osaka City University
(Osaka, Japan, reference number 2794) with waiver of
informed consent because of its retrospective design.
Written informed consent for the use of partitioned
plasma products was obtained from all patients before
treatment.
Statistical analysis
Associations between the duration of postoperative air
leak and clinical variables were sought using the Mann–
Whitney U test and the chi-square test. For the correlation
between FXIII and other factors, Pearson product–
moment correlation coefficient (Pearson’s r) was calcu-
lated. Receiver operating characteristic (ROC) curves were
constructed to determine the optimal cut-off point for the
effect of exogenous FXIII concentrate to distinguish be-
tween the EF and inEF groups. The area under the ROC
curve (AUC) was calculated. The threshold of statistical
significance was set at p <0.05. All statistical analyses were
performed using JMP version 10.0 (SAS Institute, Cary,
NC, USA).
Results
The median age of the 90 patients with air leak on the
first postoperative day after pulmonary lobectomy was
67 years, the median BMI was 21.2 kg/m2, and the
majority (72 patients, 80.0%) was male (Table 1). While
the median of their respiratory function tests lay within
the normal range, 59% had been diagnosed with COPD
or IP clinically or on imaging studies. Upper lobectomy
or bilobectomy was undertaken in 58 patients (64.4%),
which was a significantly greater proportion than those
with no air leak on the first postoperative day (99 of 193
patients, 51.3%; p = 0.038). Pleural adhesions were ob-
served in 55 patients (61.1%), 14 of whom had extensive
adhesions (covering more than the surface of one lobe).
Intraoperative air leaks were detected and treated in 87
patients (96.7%), nine by spraying fibrin glue, four by su-
turing alone, two by overlaying a polyglycolic acid sheetwith fibrin glue and 24 by suturing followed by fibrin
glue spray, but the majority (48 patients, 53% of all, or
55% of 87 patients) were treated using all three
approaches. On the first postoperative day, air leak was
only detectable with coughing in 36 patients (40%), but
12 (13%) had a continuous leak. Air leak on normal ex-
piration was evident in the remaining 42 patients (47%).
The original air leak grading system proposed by Cerfolio
and coworkers also defined “inspiratory only” category
[20], but there were no patients with such an air leak in
our cohort. The median duration of postoperative air leak
was 4 days (range, 2–21 days), and the median duration of
drainage was 6 days (range, 2–29 days).
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istics of the SR and PAL groups. The median durations
of air leak and drainage in the SR group were 3 days
(interquartile range [IQR], 2–4 days) and 5 days (IQR,
4–6 days), respectively. In the PAL group, the median
duration of air leak and drainage were both significantly
longer: 7 days (IQR, 6–10 days) and 10 days (IQR, 7–16
days), respectively (p <0.001 for both). The method used
to repair intraoperative air leak appeared to influence
the risk of PAL: the PAL group contained a significantly
greater proportion of patients treated with both a poly-
glycolic acid sheet and suturing (p = 0.008). There were
also significant differences between the SR and PAL
groups in terms of the amount of air leak on the first
postoperative day and change in plasma FXIII activity.
The proportion of patients with continuous air leak on
the first postoperative day was significantly lower in theTable 2 Comparison of the clinical characteristics of patients











Operative procedure (upper or bilobectomy/other) 35/18
Pleural Adhesion (major/minor or no) 7/46
Repair air leak during operation
No 9
PGA sheet or suture 23
Both PGA and suture 21
Fibrin glue during operation (Yes/No) 48/5
Air leak at first postoperative day
Forced expiratory only 23
Expiratory only 28
Continuous 2
Duration of air leak (days) 3 (2–4)
Duration of drainage (days) 5 (4–6)
Drainage amount in 5 days (ml) 1105 (8
Plasma FXIII activity (%)
Before operation 104 (86
Postoperative day 5 74 (60–
Decrease ratio (%) 33 (18–
Results are expressed as median and interquartile range.
Abbreviations: FXIII factor XIII, SR spontaneous resolution group, PAL prolonged air leSR group than the PAL group (4% versus 27%, respect-
ively; p = 0.006). The SR group also exhibited a signifi-
cantly greater decrease ratio in plasma FXIII activity on
the fifth postoperative day compared with the PAL group
(33% versus 22%, p = 0.044). There were no significant
differences in preoperative or postoperative FXIII activity
between the groups.
Table 3 shows the clinical characteristics of the EF and
inEF groups. We did not detect any side effects or
adverse events attributable to the administration of
exogenous factor XIII concentrate. Patients in the inEF
group were significantly older (68 years versus 72 years,
p = 0.018) and had lower BMI (p <0.001) than the EF
group. Interestingly, the postoperative plasma FXIII ac-
tivity of patients in the EF group was significantly lower
than those in the inEF group (74% versus 91%, p =
0.030), but not significantly different from those in thewith or without spontaneous resolution of pulmonary air
PAL P value
30/7 0.83
72) 69 (64–73) 0.562




6.0–79.1) 70.8 (63.0–77.2) 0.325













49–1485) 1207 (1014–1542) 0.493
–135) 111 (95–132) 0.678
87) 78 (68–103) 0.124
45) 22 (7–36) 0.044
ak (>5 days) group, BMI body mass index, PGA polyglycolic acid.
Table 3 Comparison of clinical characteristics of patients in whom factor XIII concentrate was effective for persistent
air leak and those in whom it was ineffective
Variables EF inEF P value
Sex (Male/Female) 21/5 9/2 0.941
Age 68 (61–72) 72 (69–77) 0.018
BMI 21.4 (19.9–24.9) 18.7 (18.0–19.4) <0.001
Smoking Index 950 (600–1783) 940 (600–1400)
Ever-smoker/Never 22/4 10/1 0.609
Diabetes (Yes/No) 6/20 3/8 0.786
FEV1.0% 71.1 (59.6–77.2) 70.0 (64.9–83) 0.561
DLCO% 84.4 (72.4–104.1) 82.3 (68.6–99.9) 0.698
COPD/IP (Yes/ No) 15/11 9/2 0.160
Operative procedure (upper or bilobectomy/other) 17/9 6/5 0.534
Pleural Adhesion (major/minor or no) 6/20 1/10 0.321
Repair air leak during operation
No 3 0 0.137
PGA sheet or suture 3 4
Both PGA and suture 20 7
Fibrin glue during operation (Yes/No) 25/1 10/1 0.519
Air leak at first postoperative day
Forced expiratory only 8 5 0.276
Expiratory only 12 2
Continuous 6 4
Duration of air leak (days) 7 (6–9) 15 (10–19) <0.001
Duration of drainage (days) 8 (7–11) 17 (15–22) <0.001
Drainage amount of 5 days (ml) 1220 (1050–1543) 1054 (626–1554) 0.291
Plasma factor XIII activity (%)
Before operation 110 (89–130) 123 (99–147) 0.394
Postoperative day 5 74 (64–86) 91 (77–125) 0.030
Decrease ratio (%) 24 (7–39) 14 (1–36) 0.393
Results are expressed as median and interquartile range.
Abbreviations: EF group of patients in whom the air leak resolved during FXIII administration, inEF group of patients who required additional intervention despite
FXIII, BMI body mass index, COPD chronic obstructive pulmonary disease, DLCO carbon monoxide diffusing capacity, FEV1.0% forced expiratory volume in 1 s
(predicted), IP interstitial pneumonia, PGA polyglycolic acid.
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in the perioperative change in plasma FXIII activity
between the EF and inEF groups (24% versus 14%, p =
0.393), or between the SR and EF groups (33% versus
24%, p = 0.171); however, there was a significant differ-
ence in the perioperative change in FXIII between the
SR and inEF groups (33% versus 14%, p = 0.048). Pa-
tients’ age, BMI and postoperative FXIII activity showed
either no (FXIII and age: Pearson product–moment
correlation coefficient = 0.03) or weak (FXIII and BMI:
correlation coefficient = −0.24) correlations.
Finally, we analyzed the ROC curve to estimate the
optimal cut-off value of postoperative plasma factor XIII
activity to identify patients likely to respond to treatment
with exogenous FXIII concentrate. The area under theROC curve for postoperative FXIII activity was 0.751
(Figure 2). The optimal cut-off point for postoperative
FXIII activity was 86%, at which the overall sensitivity
for predicting resolution of air leak during FXIII therapy
was 80.7% (21 of the 26 patients in whom air leak re-
solved during FXIII therapy) and the overall specificity
was 72.7% (eight of 11 patients in whom air leak
persisted despite FXIII therapy).
Discussion
Prolonged air leak is a common complication of pul-
monary resection that can have serious consequences,
and has the potential to prolong hospital stay [2]. Several
techniques and therapies have been developed to address
PAL, such as the pleural tent technique [21], the use of
Sensitivity: 80.7%
Specificity: 72.7%
















Figure 2 Receiver operating characteristic (ROC) curve for
postoperative plasma factor XIII activity in the EF and inEF
groups. Area under the curve (AUC) = 0.751. The calculated optimal
cut-off point for factor XIII activity on the fifth postoperative day to
distinguish effectiveness of exogenous factor XIII concentrate
administration was 86% (Youden Index = 0.535); the overall sensitivity
was 80.7% and the overall specificity was 72.7%.
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different chest drainage management strategies [24].
Nonetheless, the choices remain relatively limited and
their results inconsistent, apart from the more invasive
procedures.
In our cohort, three significant risk factors for PAL
were detected: a reduced proportional reduction in the
activity of FXIII, which likely reflects impaired consump-
tion of FXIII; the method used to repair any intraopera-
tive air leak detected; and the amount of air leak on the
first postoperative day, which also reflected the outcome
of efforts to effect an intraoperative repair. Risk factors
reported by other investigators, such as age, BMI or FEV
[5-7], did not appear to play a role in our cohort, but
this may have arisen as a result of selection bias. The
subjects of previous studies included patients with no air
leak after surgery, who were excluded from our analysis.
This would likely have eliminated the risk factors for
developing an air leak, allowing us to assess the influence
of a variety of perioperative factors on the maintenance
of a leak and thereby those contributing to a delay in the
healing of a pulmonary fistula. As the perioperative
change in plasma FXIII activity was the only factor that
appeared to influence PAL resolution in our cohort, it
may play a role in the prompt closure of postoperative
air leaks.
Blood coagulation FXIII was initially identified as a
component of the hemostatic system [25]. It exists inplasma as a heterotetramer consisting of two enzymatic
A-subunits synthesized by cells of bone marrow origin,
and two carrier/inhibitor B-subunits synthesized by he-
patocytes. In the final stage of the coagulation cascade,
circulating FXIII is bound to fibrinogen and activated by
thrombin and calcium ions. Activated FXIII, which is a
transformed A-subunit dimer, then cross-links fibrin
chains and stabilizes them. Recently, it has become clear
that FXIII is also involved in wound healing. Studies of
FXIII-deficient animals [26] and patients with acquired
or inherited FXIII deficiency [27-30] reported that the
level of plasma FXIII activity influences the time taken
for wound healing. Cario et al. found that FXIII signifi-
cantly enhanced epithelial restitution in vitro in a TGF-
β-independent manner [17], and Inbal et al. showed that
impaired wound healing could be restored by replenish-
ing plasma FXIII with human FXIII concentrate in a
mouse experimental model [26].
We compared the EF group and inEF group to exam-
ine the effect of exogenous FXIII concentrate adminis-
tration. The EF group was significantly younger, had
higher BMI and had significantly lower postoperative
plasma FXIII activity compared with the inEF group. As
there were no significant correlations between post-
operative FXIII activity, age and BMI, each of these fac-
tors may have an independent effect on the outcome of
administration of exogenous FXIII concentrate. This is
the first occasion on which these perioperative changes
in FXIII activity have been described: the SR group had
the lowest postoperative FXIII activity (74%) and the lar-
gest proportional perioperative decrease in FXIII activity
(33%) of all groups. Postoperative FXIII activity was not
statistically different in the EF group, but the perioperative
decrease was only 24%. Interestingly, postoperative FXIII
activity was highest (91%) in the inEF group, and activity
had only fallen by 14% by the fifth postoperative day.
Our findings suggest that there could be two separate
mechanisms underpinning PAL. First, PAL may be a
consequence of insufficient plasma FXIII activity, and
may therefore respond to treatment with exogenous
FXIII concentrate. This type of PAL would be character-
ized by low postoperative FXIII activity, which would be
reflected by a relatively low proportional change in activ-
ity compared with patients in whom air leak resolves
spontaneously. In support of this hypothesis, we found
that PAL resolved in 85% of patients within 3 days of
starting exogenous FXIII concentrate treatment (data
not shown) in the EF group. The second type of PAL
could be caused by a lack of consumption of FXIII, the
postoperative activity of which is therefore higher and
the proportional perioperative decrease lower. We can-
not, however, draw any conclusions about why FXIII
consumption would be disordered in these patients from
the results of this study. As patients in the inEF group
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adhesion therapy to promote wound healing cascade, or
secondary surgery to physically close the wound, a
potential explanation is that the blood coagulation and
wound healing cascades had become exhausted and
consumption of factor XIII had ceased before the reso-
lution of air leak. For this type of PAL, administration of
additional exogenous FXIII concentrate might not be
effective.
We found that the optimal cut-off point of postopera-
tive plasma FXIII activity that differentiated between the
EF and inEF groups most effectively was 86%, compared
with a cut-off of 70% reported in a previous study [31].
Given the limitations of our study design and the relatively
small sample size, we recommend that other clinical
factors are also taken into account when determining
treatment strategies for patients with PAL in addition to
the use of factor XIII concentrate.
Conclusions
We found that plasma FXIII appears to play an import-
ant role in closing pulmonary fistulae in patients with
PAL after pulmonary lobectomy for non-small cell lung
cancer. In 85% of the EF group, air leaks resolved within
3 days of commencing exogenous FXIII concentrate
treatment, and no apparent adverse events were ob-
served. Interestingly, plasma FXIII activity fell less
during the course of treatment in those in whom PAL
did not resolve, suggesting that lack of consumption or
utilization of endogenous FXIII may delay healing of
pulmonary fistulae. As a non-invasive treatment, this
strategy is a particularly useful and safe therapeutic op-
tion for those who might not tolerate more invasive
therapies. Nonetheless, as our study design was observa-
tional and retrospective, and was conducted in a single
center, further randomized controlled prospective stud-
ies with larger numbers of subjects will be needed to
validate our findings.
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